3-hydroxybenzylhydrazine has been researched along with Obesity in 1 studies
3-hydroxybenzylhydrazine: decarboxylase inhibitor; RN given refers to parent cpd; structure
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koulu, M | 1 |
| Huupponen, R | 1 |
| Hänninen, H | 1 |
| Pesonen, U | 1 |
| Rouru, J | 1 |
| Seppälä, T | 1 |
1 other study available for 3-hydroxybenzylhydrazine and Obesity
| Article | Year |
|---|---|
Hypothalamic neurochemistry and feeding behavioral responses to clonidine, an alpha-2-agonist, and to trifluoromethylphenylpiperazine, a putative 5-hydroxytryptamine-1B agonist, in genetically obese Zucker rats.
Topics: 5-Hydroxytryptophan; Adrenergic alpha-Agonists; Animals; Aromatic Amino Acid Decarboxylase Inhibitor | 1990 |